Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Generation Biotech LLC is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, which indicates a highly concentrated prosecution effort for the company's current applications. The data shows that the examination is taking place within 1 distinct art unit, suggesting that the technical subject matter is focused within a specific area of biotechnology.
The busiest examiner for this portfolio is MUMMERT, STEPHANIE KANE, who is currently handling 1 busiest examiner pending office action. This 1 busiest examiner pending office action represents the entirety of the company's current pending workload at the patent office. Consequently, the progress of the filings in the Biotechnology & Pharmaceuticals sector is currently tied to the review and decision-making of the identified examiner.
For practitioners, the presence of 1 distinct art unit and 1 distinct examiner means there is no variability in the current examination environment. The strategy for Generation Biotech LLC depends on the specific requirements and preferences of MUMMERT, STEPHANIE KANE. Navigating the pending matter requires a focused approach that addresses the specific concerns of the examiner within the identified art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MUMMERT, STEPHANIE KANE | 1 | 61.2% | +21.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18220552 | METHODS FOR CAPTURING LONG POLYNUCLEOTIDES FOR SEQUENCING SPECIFIC GENOMIC REGIONS | MUMMERT, STEPHANIE KANE | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18220552 | METHODS FOR CAPTURING LONG POLYNUCLEOTIDES FOR SEQUENCING SPECIFIC GENOMIC REGIONS | MUMMERT, STEPHANIE KANE | 1681 | §103DP | Non-Final OA | — | Pending | Jul 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial